Association between Serum Thyroid Stimulating Hormone Level and Papillary Thyroid Microcarcinoma in Korean Euthyroid Patients

다국어 초록 (Multilingual Abstract)

Background: Thyroid cancer is a common disease and its prevalence is increasing. Recent reports have shown that an elevated thyrotropin (thyroid stimulating hormone, TSH) level is associated with thyroid cancer risk. However, the association between TSH level and thyroid cancer risk is not yet known for euthyroid patients diagnosed with papillary thyroid microcarcinoma (PTMC).
Methods: Our study included 425 patients who underwent thyroid surgery and were diagnosed with PTMC between 2008 and 2009. Control group patients were diagnosed with benign nodules ≤ 1 cm in size by US-guided fine needle aspiration. Nodules with one or more suspected malignant-ultrasonographic feature(s) were excluded from this study. Patients who were not euthyroid or who took thyroid medication were also excluded.
Results: The mean age of all patients was 48.5 ± 11.0 years and 88.8% were women. The mean age of those with PTMC was significantly lower than that of the control group. The mean TSH level was 1.78 ± 0.93 mIU/L, and the mean free T4 level was 15.96 ± 2.32pmol/L. There was no difference in TSH level between the PTMC and control groups (1.77 ± 0.93 mIU/L vs. 1.79 ± 0.91 mIU/L, P =0.829). After adjusting for age, TSH level was not correlated with tumor size (r = 0.02, P = 0.678) in the PTMC group. Moreover, the TSH level did not differ between patients with stage I and stage III-IV carcinoma (stage I, 1.77 ± 0.95 mIU/L; stage III–IV, 1.79 ± 0.87mIU/L; P = 0.856).
Conclusion: TSH levels are not elevated in euthyroid PTMC patients. Thus, further evaluation is needed before serum TSH can be used as a tumor marker for small nodules ≤ 1 cm in size in euthyroid patients.

참고문헌 (Reference)

1 Gerschpacher M, "Thyrotropin serum concentrations in patients with papillary thyroid microcancers" 20 : 389-392, 2010

2 Biondi B, "Thyroid-hormone therapy and thyroid cancer: a reassessment" 1 : 32-40, 2005

3 Sherman SI, "Thyroid carcinoma" 361 : 501-511, 2003

4 Sipos JA, "The therapeutic management of differentiated thyroid cancer" 9 : 2627-2637, 2008

5 Hedinger C, "The WHO histological classification of thyroid tumors: a commentary on the second edition" 63 : 908-911, 1989

6 Patel SG, "TNM staging of cancers of the head and neck: striving for uniformity among diversity" 55 : 242-258, 2005

7 Boelaert K, "Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration" 91 : 4295-4301, 2006

8 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer" 19 : 1167-1214, 2009

9 Yoshihara A, "Reference limits for serum thyrotropin in a Japanese population" 58 : 585-588, 2011

10 Kim TY, "Prognostic parameters for recurrence of papillary thyroid microcarcinoma" BioMed Central 8 : 296-, 2008

11 최윤정, "Prevalence of Thyroid Cancer at a Medical Screening Center: Pathological Features of Screen-detected Thyroid Carcinomas" 연세대학교의과대학 49 (49): 748-756, 2008

12 Noguchi S, "Papillary microcarcinoma" 32 : 747-753, 2008

13 Yamamoto Y, "Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases" 65 : 1173-1179, 1990

14 Strate SM, "Occult papillary carcinoma of the thyroid with distant metastases" 54 : 1093-1100, 1984

15 Lim AK, "Measurement of serum TSH in the investigation of patients presenting with thyroid enlargement" 91 : 687-689, 1998

16 Fiore E, "Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role" 16 : 1251-1260, 2009

17 Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer" 97 : 418-428, 1994

18 Papini E, "Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules" 83 : 780-783, 1998

19 Davies L, "Increasing incidence of thyroid cancer in the United States, 1973-2002" 295 : 2164-2167, 2006

20 Haymart MR, "Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage" 93 : 809-814, 2008

21 Shi Y, "Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis" 39 : 269-274, 1993

22 Jonklaas J, "Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer" 18 : 943-952, 2008

23 Derwahl M, "Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors" 84 : 829-834, 1999